PMID- 11399579
OWN - NLM
STAT- Publisher
LR  - 20191120
IS  - 1607-8454 (Electronic)
IS  - 1024-5332 (Linking)
VI  - 4
IP  - 5
DP  - 2000
TI  - Haemostasis and Thrombosis: Current Clinical Practice: Low-Molecular-Weight 
      Heparins in The Prophylaxis and Treatment of Thrombo-Embolic Disease.
PG  - 373-380
AB  - Low-Molecular-Weight Heparin (LMWH) fractions are prepared from standard 
      unfractionated heparin (UFH) and are thus similar to it in many aspects. The 
      major advantages of LMWH are improved efficacy and safety, longer half-life and 
      reduced need for laboratory monitoring. In addition, the dangers of UFH 
      administered by continuous infusion in the hospital setting are often not fully 
      appreciated and the necessary monitoring and dosage adjustment poorly carried out 
      resulting in inadequate doses being given. LMWHs are the drug of choice in many 
      clinical situations. Four LMWHs are now licensed in the UK for prophylaxis of 
      venous thrombo-embolism during or after surgery (Certoparin, Dalteparin 
      [Fragmin], Enoxaparin [Lovenox/Clexane] and Tinzaparin [Innohep]; a fifth is 
      licensed but not currently available in the UK. Dalteparin, Enoxaparin and 
      Tinzaparin are licensed for the treatment of Deep Vein Thrombosis (DVT), and 
      Tinzaparin additionally for the treatment of Pulmonary Embolism (PE), but so far 
      none is licensed for use in pregnancy or paediatrics.
FAU - O'Shaughnessy, DENISE F
AU  - O'Shaughnessy DF
AD  - Consultant Haematologist, Southampton University Hospital NHS Trust, Southampton.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Hematology
JT  - Hematology (Amsterdam, Netherlands)
JID - 9708388
EDAT- 2001/06/16 10:00
MHDA- 2001/06/16 10:00
CRDT- 2001/06/16 10:00
PHST- 2001/06/16 10:00 [pubmed]
PHST- 2001/06/16 10:00 [medline]
PHST- 2001/06/16 10:00 [entrez]
AID - I458L991054 [pii]
PST - ppublish
SO  - Hematology. 2000;4(5):373-380.